Erdem Çubukçu

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 689 citations · Full text

Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy

Ahmet Bilgehan Şahin, Erdem Çubukçu, Birol Ocak et al. · Scientific Reports · 2021 · 113 citations · Full text

Aurora A overexpression in breast cancer patients induces taxane resistance and results in worse prognosis.

Yalcin Cirak, Yavuz Furuncuoğlu, Asude Aksu et al. · PubMed · 2016 · 53 citations

Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?

Arife Ulaş, Fahriye Tuğba Köş, Erdem Çubukçu et al. · PubMed · 2015 · 49 citations

Medication Errors in Chemotherapy Preparation and Administration: a Survey Conducted among Oncology Nurses in Turkey

Arife Ulaş, Didem Şener Dede, Muhammed Bülent Akıncı et al. · Asian Pacific Journal of Cancer Prevention · 2015 · 45 citations · Full text